Equity Profile

CYTK

Cytokinetics, Incorporated

Health CareBiotechnology$10.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Cytokinetics, Incorporated is a biotechnology company focused on developing treatments for serious diseases, particularly those affecting muscle function. With a market cap of $10 billion, it plays a significant role in the health care sector, aiming to address unmet medical needs through innovative therapies.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is vital for future funding and development.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CYTK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-10.29%

Avg Stock Reaction

+3.00%

Last Quarter Recap

In Q1-2026, Cytokinetics reported an EPS of -$1.67, matching analyst expectations. The stock saw a positive reaction, rising 16.71% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the recent stock performance despite ongoing losses.

Bull Case

If Cytokinetics can demonstrate significant progress in its clinical trials or show better-than-expected revenue growth, it could lead to a strong rally in the stock.

Bear Case

Conversely, if the company reports wider losses or delays in clinical trials, it may lead to a sharp decline in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and any expected timelines for results?

The market will closely watch for updates on clinical trials, as these can significantly influence the company's future prospects and stock price.

How does the company plan to address its recent financial losses moving forward?

Investors will be keen to hear management's strategy for improving financial performance, which is crucial for maintaining investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Cytokinetics to achieve better-than-expected results in its clinical trials, which could lead to a positive surprise.

Supporting Evidence

The stock has shown resilience with a 16.71% increase following the last earnings report, indicating potential investor confidence.

Options pricing suggests a significant move, indicating that traders expect volatility which could favor a positive outcome.

Key Risk

If clinical trial results exceed expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Cytokinetics can show progress in its clinical trials while managing its financial losses.

Bull Confirmed If

Demonstrating a reduction in losses to less than -$1.50 EPS would signal improved operational efficiency.

Bear Confirmed If

Reporting losses greater than -$1.75 EPS could raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±19.61%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±19.6% while CYTK has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

60.5%

Calls (23K)P/C Ratio: 0.01Puts (12K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

18,449 sh

3 insiders

Net

$1.2M

Net selling

Most Active Insiders· 3 open-market trades

EVP, Chief Commercial OfficerCallos Andrew
$491,782.98

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cytokinetics beats expectations, history suggests a potential stock increase of around 5.17%, confirming a positive outlook.

In-Line / Cautious

If the results are in line with expectations but lack strong guidance, the stock may experience moderate volatility without a clear direction.

Miss

Should the company miss expectations, history suggests a decline of approximately 5.17%, which could lead to increased scrutiny from investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines and results of ongoing clinical trials.
2Management's strategy for addressing recent financial losses.
3Any new partnerships or collaborations that could enhance product development.
4Insights into market demand for their therapies and how they plan to capture it.
5Future guidance on revenue expectations and operational efficiency improvements.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is vital for future funding and development.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CYTK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-10.29%

Avg Stock Reaction

+3.00%

Last Quarter Recap

In Q1-2026, Cytokinetics reported an EPS of -$1.67, matching analyst expectations. The stock saw a positive reaction, rising 16.71% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the recent stock performance despite ongoing losses.

Bull Case

If Cytokinetics can demonstrate significant progress in its clinical trials or show better-than-expected revenue growth, it could lead to a strong rally in the stock.

Bear Case

Conversely, if the company reports wider losses or delays in clinical trials, it may lead to a sharp decline in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and any expected timelines for results?

The market will closely watch for updates on clinical trials, as these can significantly influence the company's future prospects and stock price.

How does the company plan to address its recent financial losses moving forward?

Investors will be keen to hear management's strategy for improving financial performance, which is crucial for maintaining investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Cytokinetics to achieve better-than-expected results in its clinical trials, which could lead to a positive surprise.

Supporting Evidence

The stock has shown resilience with a 16.71% increase following the last earnings report, indicating potential investor confidence.

Options pricing suggests a significant move, indicating that traders expect volatility which could favor a positive outcome.

Key Risk

If clinical trial results exceed expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Cytokinetics can show progress in its clinical trials while managing its financial losses.

Bull Confirmed If

Demonstrating a reduction in losses to less than -$1.50 EPS would signal improved operational efficiency.

Bear Confirmed If

Reporting losses greater than -$1.75 EPS could raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±19.61%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±19.6% while CYTK has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

60.5%

Calls (23K)P/C Ratio: 0.01Puts (12K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

18,449 sh

3 insiders

Net

$1.2M

Net selling

Most Active Insiders· 3 open-market trades

EVP, Chief Commercial OfficerCallos Andrew
$491,782.98

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cytokinetics beats expectations, history suggests a potential stock increase of around 5.17%, confirming a positive outlook.

In-Line / Cautious

If the results are in line with expectations but lack strong guidance, the stock may experience moderate volatility without a clear direction.

Miss

Should the company miss expectations, history suggests a decline of approximately 5.17%, which could lead to increased scrutiny from investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines and results of ongoing clinical trials.
2Management's strategy for addressing recent financial losses.
3Any new partnerships or collaborations that could enhance product development.
4Insights into market demand for their therapies and how they plan to capture it.
5Future guidance on revenue expectations and operational efficiency improvements.